{"version":"1.0","provider_name":"EnterpriseAM Egypt","provider_url":"https:\/\/enterpriseam.com\/egypt","author_name":"enterpriseam admin","author_url":"https:\/\/enterpriseam.com\/egypt\/author\/enterpriseam\/","title":"Why big pharma is turning to biological meds","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"1xs050FJCu\"><a href=\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/\">Why big pharma is turning to biological meds<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/enterpriseam.com\/egypt\/2017\/04\/13\/why-big-pharma-is-turning-to-biological-meds\/embed\/#?secret=1xs050FJCu\" width=\"600\" height=\"338\" title=\"&#8220;Why big pharma is turning to biological meds&#8221; &#8212; EnterpriseAM Egypt\" data-secret=\"1xs050FJCu\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/enterpriseam.com\/egypt\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/ent.news\/2017\/4\/2285.jpg","thumbnail_width":1,"thumbnail_height":1,"description":"Why big pharma is turning to biological meds: Biological meds are increasingly being seen as more lucrative to pharma companies than the standard chemical kinds. While chemical drugs are based on small, stable molecules (and have been used since the industry emerged), their biological counterparts are based on much larger and more volatile proteins. Despite [&hellip;]"}